Literature DB >> 18221290

The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action.

Malcolm Carruthers1.   

Abstract

INTRODUCTION: Central to the diagnosis and treatment of testosterone deficiency syndrome in the adult male is the remarkable paradox that there is a very poor correlation between the characteristic symptoms and levels of serum androgens. AIM: Because androgen deficiency can be associated with severe symptomatology, as well as diverse conditions such as coronary heart disease, diabetes, and metabolic syndrome, the aim was to present an evidence-based working hypothesis to resolve this confusing clinical paradox.
METHODS: A review of the possible mechanisms in testosterone deficiency syndrome was carried out, and a hypothesis to explain this paradox and associated problems in the diagnosis and clinical management of androgen deficiency was established on the basis of a review of the literature. MAIN OUTCOME MEASURES: The mechanisms by which androgen deficiency could arise were studied at five different levels: 1. Impaired androgen synthesis or regulation. 2. Increased androgen binding. 3. Reduced tissue responsiveness. 4. Decreased androgen receptor activity. 5. Impaired transcription and translation.
RESULTS: As with insulin in maturity onset diabetes mellitus, there can be both insufficient production and variable degrees of resistance to the action of androgens operating at several levels in the body simultaneously, with these factors becoming progressively worse with aging, adverse lifestyle, other disease processes, and a wide range of medications.
CONCLUSIONS: Using this model, androgen deficiency can be redefined as an absolute or relative deficiency of androgens or their metabolites according to the needs of that individual at that time in his life. There are important ways in which the considerations raised by this hypothesis affect the etiology, terminology, diagnosis, and treatment of androgen-deficient states.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18221290     DOI: 10.1111/j.1743-6109.2007.00721.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  6 in total

Review 1.  Testicular cancer survivorship: research strategies and recommendations.

Authors:  Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Journal:  J Natl Cancer Inst       Date:  2010-06-28       Impact factor: 13.506

2.  International web survey shows high prevalence of symptomatic testosterone deficiency in men.

Authors:  Tom R Trinick; Mark R Feneley; Hugh Welford; Malcolm Carruthers
Journal:  Aging Male       Date:  2010-09-09       Impact factor: 5.892

Review 3.  Could androgens maintain specific domains of mental health in aging men by preserving hippocampal neurogenesis?

Authors:  Mark I Ransome
Journal:  Neural Regen Res       Date:  2012-10-05       Impact factor: 5.135

4.  Evolution of testosterone treatment over 25 years: symptom responses, endocrine profiles and cardiovascular changes.

Authors:  Malcolm Carruthers; Paul Cathcart; Mark R Feneley
Journal:  Aging Male       Date:  2015-07-28       Impact factor: 5.892

Review 5.  Are the adverse effects of glitazones linked to induced testosterone deficiency?

Authors:  M Carruthers; T R Trinick; E Jankowska; A M Traish
Journal:  Cardiovasc Diabetol       Date:  2008-10-15       Impact factor: 9.951

6.  Time for international action on treating testosterone deficiency syndrome.

Authors:  Malcolm Carruthers
Journal:  Aging Male       Date:  2009-03       Impact factor: 5.892

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.